19. Lysosomal storage disease Clinical trials / Disease details


Clinical trials : 854 Drugs : 716 - (DrugBank : 105) / Drug target genes : 70 - Drug target pathways : 191

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00446862
(ClinicalTrials.gov)
March 200711/3/2007The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) StudyMulti-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET StudyFabry Disease;ProteinuriaDrug: enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockersUniversity of Alabama at BirminghamNULLCompleted19 Years85 YearsBoth36N/AUnited States;Slovenia;Germany